Market Overview

UPDATE: Deutsche Bank Reiterates on Amgen Following Biosimilar Conference

Related AMGN
Benzinga's M&A Chatter for Wednesday October 7, 2015
Amgen Announces Repatha™ Co-Preferred Position on Express Scripts National Formulary
Biotech Sell-Off: Temporary, Or Here To Stay? (Seeking Alpha)

In a report published Wednesday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating on Amgen (NASDAQ: AMGN), and raised the price target from $138.00 to $142.00.

In the report, Deutsche Bank noted, “We attended a biosimilar conference in order to learn more about the OPP'Y for Amgen. We came away with a greater understanding as to the impact of Biosimilars on AMGN's base biz & have adjusted our model accordingly. We also grew more comfortable in the Biosmilar opp'y for AMGN. We now include a probability adjusted Biosimilar revs beyond 2017 & note net/net biosimilars have a positive NPV to AMGN. Please ask for our Biosimilar APP.”

Amgen closed on Tuesday at $115.46.

Latest Ratings for AMGN

Sep 2015NomuraMaintainsBuy
Sep 2015UBSUpgradesNeutralBuy
Jul 2015BarclaysMaintainsEqual-weight

View More Analyst Ratings for AMGN
View the Latest Analyst Ratings

Posted-In: Deutsche Bank Robyn KarnauskasAnalyst Color Price Target Analyst Ratings


Related Articles (AMGN)

View Comments and Join the Discussion!

Get Benzinga's Newsletters